Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children

Filippo Spreafico, Maura Massimino, Roberto Luksch, Michela Casanova, Graziella S. Cefalo, Paola Collini, Andrea Ferrari, Daniela Polastri, Monica Terenziani, Marco Gasparini, Franca Fossati-Bellani

Research output: Contribution to journalArticle

Abstract

Purpose: To improve the 63% event-free survival (EFS) achieved before 1986 in Murphy's stage III to IV Burkitt's lymphoma (BL), both chemotherapy and supportive care were intensified. Patients and Methods: From May 1987 to February 2001, 60 children, median age 9 years (range, 2.1 to 17 years), with advanced BL were enrolled onto two sequential institutional studies. From 1987 to 1992, 30 patients were stratified according to the absence (regimen IA, n = 19) or presence (regimen IB, n = 11) of bone marrow (BM) or CNS involvement. After 5-week cytoreductive chemotherapy consisting of vincristine, cyclophosphamide, doxorubicin, high-dose (HD) methotrexate (MTX), and intrathecal MTX or cytarabine, HD cytarabine and cisplatin were provided as a 4-day continuous infusion. Regimen IB was intensified by adding etoposide and HD ifosfamide and escalating MTX doses. Since 1992, regardless of BM or CNS status, 30 patients have been placed on regimen II, which is identical to IB but without ifosfamide. The scheduled duration of regimen II was 45 days. Results: EFS and disease-free survival at 5 years are 81% ± 5% and 87% ± 5%, respectively, for 59 assessable patients (73% ± 8% and 85% ± 7% for regimen IA + IB, 89% ± 6%, EFS and disease-free survival, for regimen II; median follow-up, 6.7 years; range, 0.6 to 13.5 years). Six patients, two of whom were receiving regimen II, died as a result of initial treatment failure or relapse, and five patients, none receiving regimen II, died as a result of treatment-related complications. Conclusion: This 45-day intensive chemotherapy program is the shortest schedule for disseminated BL and overcomes previously recognized risk factors such as BM and CNS infiltration.

Original languageEnglish
Pages (from-to)2783-2788
Number of pages6
JournalJournal of Clinical Oncology
Volume20
Issue number12
DOIs
Publication statusPublished - Jun 15 2002

Fingerprint

Burkitt Lymphoma
Disease-Free Survival
Drug Therapy
Methotrexate
Ifosfamide
Bone Marrow
Cytarabine
Vincristine
Etoposide
Treatment Failure
Doxorubicin
Cyclophosphamide
Cisplatin
Appointments and Schedules
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. / Spreafico, Filippo; Massimino, Maura; Luksch, Roberto; Casanova, Michela; Cefalo, Graziella S.; Collini, Paola; Ferrari, Andrea; Polastri, Daniela; Terenziani, Monica; Gasparini, Marco; Fossati-Bellani, Franca.

In: Journal of Clinical Oncology, Vol. 20, No. 12, 15.06.2002, p. 2783-2788.

Research output: Contribution to journalArticle

@article{617b6807b0de491aa231dd02da33151c,
title = "Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children",
abstract = "Purpose: To improve the 63{\%} event-free survival (EFS) achieved before 1986 in Murphy's stage III to IV Burkitt's lymphoma (BL), both chemotherapy and supportive care were intensified. Patients and Methods: From May 1987 to February 2001, 60 children, median age 9 years (range, 2.1 to 17 years), with advanced BL were enrolled onto two sequential institutional studies. From 1987 to 1992, 30 patients were stratified according to the absence (regimen IA, n = 19) or presence (regimen IB, n = 11) of bone marrow (BM) or CNS involvement. After 5-week cytoreductive chemotherapy consisting of vincristine, cyclophosphamide, doxorubicin, high-dose (HD) methotrexate (MTX), and intrathecal MTX or cytarabine, HD cytarabine and cisplatin were provided as a 4-day continuous infusion. Regimen IB was intensified by adding etoposide and HD ifosfamide and escalating MTX doses. Since 1992, regardless of BM or CNS status, 30 patients have been placed on regimen II, which is identical to IB but without ifosfamide. The scheduled duration of regimen II was 45 days. Results: EFS and disease-free survival at 5 years are 81{\%} ± 5{\%} and 87{\%} ± 5{\%}, respectively, for 59 assessable patients (73{\%} ± 8{\%} and 85{\%} ± 7{\%} for regimen IA + IB, 89{\%} ± 6{\%}, EFS and disease-free survival, for regimen II; median follow-up, 6.7 years; range, 0.6 to 13.5 years). Six patients, two of whom were receiving regimen II, died as a result of initial treatment failure or relapse, and five patients, none receiving regimen II, died as a result of treatment-related complications. Conclusion: This 45-day intensive chemotherapy program is the shortest schedule for disseminated BL and overcomes previously recognized risk factors such as BM and CNS infiltration.",
author = "Filippo Spreafico and Maura Massimino and Roberto Luksch and Michela Casanova and Cefalo, {Graziella S.} and Paola Collini and Andrea Ferrari and Daniela Polastri and Monica Terenziani and Marco Gasparini and Franca Fossati-Bellani",
year = "2002",
month = "6",
day = "15",
doi = "10.1200/JCO.2002.08.088",
language = "English",
volume = "20",
pages = "2783--2788",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children

AU - Spreafico, Filippo

AU - Massimino, Maura

AU - Luksch, Roberto

AU - Casanova, Michela

AU - Cefalo, Graziella S.

AU - Collini, Paola

AU - Ferrari, Andrea

AU - Polastri, Daniela

AU - Terenziani, Monica

AU - Gasparini, Marco

AU - Fossati-Bellani, Franca

PY - 2002/6/15

Y1 - 2002/6/15

N2 - Purpose: To improve the 63% event-free survival (EFS) achieved before 1986 in Murphy's stage III to IV Burkitt's lymphoma (BL), both chemotherapy and supportive care were intensified. Patients and Methods: From May 1987 to February 2001, 60 children, median age 9 years (range, 2.1 to 17 years), with advanced BL were enrolled onto two sequential institutional studies. From 1987 to 1992, 30 patients were stratified according to the absence (regimen IA, n = 19) or presence (regimen IB, n = 11) of bone marrow (BM) or CNS involvement. After 5-week cytoreductive chemotherapy consisting of vincristine, cyclophosphamide, doxorubicin, high-dose (HD) methotrexate (MTX), and intrathecal MTX or cytarabine, HD cytarabine and cisplatin were provided as a 4-day continuous infusion. Regimen IB was intensified by adding etoposide and HD ifosfamide and escalating MTX doses. Since 1992, regardless of BM or CNS status, 30 patients have been placed on regimen II, which is identical to IB but without ifosfamide. The scheduled duration of regimen II was 45 days. Results: EFS and disease-free survival at 5 years are 81% ± 5% and 87% ± 5%, respectively, for 59 assessable patients (73% ± 8% and 85% ± 7% for regimen IA + IB, 89% ± 6%, EFS and disease-free survival, for regimen II; median follow-up, 6.7 years; range, 0.6 to 13.5 years). Six patients, two of whom were receiving regimen II, died as a result of initial treatment failure or relapse, and five patients, none receiving regimen II, died as a result of treatment-related complications. Conclusion: This 45-day intensive chemotherapy program is the shortest schedule for disseminated BL and overcomes previously recognized risk factors such as BM and CNS infiltration.

AB - Purpose: To improve the 63% event-free survival (EFS) achieved before 1986 in Murphy's stage III to IV Burkitt's lymphoma (BL), both chemotherapy and supportive care were intensified. Patients and Methods: From May 1987 to February 2001, 60 children, median age 9 years (range, 2.1 to 17 years), with advanced BL were enrolled onto two sequential institutional studies. From 1987 to 1992, 30 patients were stratified according to the absence (regimen IA, n = 19) or presence (regimen IB, n = 11) of bone marrow (BM) or CNS involvement. After 5-week cytoreductive chemotherapy consisting of vincristine, cyclophosphamide, doxorubicin, high-dose (HD) methotrexate (MTX), and intrathecal MTX or cytarabine, HD cytarabine and cisplatin were provided as a 4-day continuous infusion. Regimen IB was intensified by adding etoposide and HD ifosfamide and escalating MTX doses. Since 1992, regardless of BM or CNS status, 30 patients have been placed on regimen II, which is identical to IB but without ifosfamide. The scheduled duration of regimen II was 45 days. Results: EFS and disease-free survival at 5 years are 81% ± 5% and 87% ± 5%, respectively, for 59 assessable patients (73% ± 8% and 85% ± 7% for regimen IA + IB, 89% ± 6%, EFS and disease-free survival, for regimen II; median follow-up, 6.7 years; range, 0.6 to 13.5 years). Six patients, two of whom were receiving regimen II, died as a result of initial treatment failure or relapse, and five patients, none receiving regimen II, died as a result of treatment-related complications. Conclusion: This 45-day intensive chemotherapy program is the shortest schedule for disseminated BL and overcomes previously recognized risk factors such as BM and CNS infiltration.

UR - http://www.scopus.com/inward/record.url?scp=0037096890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037096890&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.08.088

DO - 10.1200/JCO.2002.08.088

M3 - Article

C2 - 12065554

AN - SCOPUS:0037096890

VL - 20

SP - 2783

EP - 2788

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -